Epidemiology study of malaria transmission intensity in sub-Saharan Africa
Trial overview
Number of participants infected with Plasmodium falciparum (P. falciparum) by World Health Organisation (WHO) age group
Timeframe: At Day 1 (survey completion visit)
Number of participants infected with P. falciparum by Joint Technical Expert Group (JTEG) age group
Timeframe: At Day 1 (survey completion visit)
Number of participants using malaria control interventions: bednet usage and type of bednet
Timeframe: At Day 1 (survey completion visit)
Number of participants using malaria control interventions: mosquito coils, insecticide sprays, commercial repellants, traditional repellants and indoor residual sprays
Timeframe: At Day 1 (survey completion visit)
Number of participants infected with P. falciparum by center, gender and infection status
Timeframe: At Day 1 (survey completion visit)
Number of participants infected with Plasmodium species other than P. falciparum
Timeframe: At Day 1 (survey completion visit)
Number of participants who received dose 3 of the Diphtheria, Tetanus, Pertussis/ Hepatitis B/ Haemophilus influenzae type b (DTP/HepB/Hib) vaccine or dose 1 of the measles vaccine
Timeframe: At Day 1 (survey completion visit)
Number of participants who received anti-malarial therapy or any other medication within 14 days prior to the study visit
Timeframe: Up to 14 days prior to the study visit at Day 1
Number of participants with measured fever at the time of their study visit
Timeframe: At Day 1 (survey completion visit)
Number of participants with reported fever in the 24 hours prior to their study visit
Timeframe: Up to 24 hours prior to their study visit at Day 1
Number of participants demonstrating care-seeking behavior following reported fever or malaria up to 14 days prior to their study visit
Timeframe: Up to 14 days prior to their study visit at Day 1
Number of participants in each geo-referenced segment
Timeframe: At Day 1 (survey completion visit)
Number of participants experiencing malaria risk factors categorized by the number of participants living in the same house (by parasite density)
Timeframe: At Day 1 (survey completion visit)
Number of participants experiencing malaria risk categorized by location (by parasite density)
Timeframe: At Day 1 (survey completion visit)
Number of participants experiencing malaria risk factors categorized by house information (by parasite density)
Timeframe: At Day 1 (survey completion visit)
Participation criteria
- Participants whose parent(s)/Legally Acceptable Representative(s) [LAR(s)], in the opinion of the investigator, could and would comply with the requirements of the protocol.
- A male or female aged 6 months to under 10 years at the time of the survey.
- Child was in care.
- Had current active participation in any trial involving administration of an investigational malaria vaccine or malaria drug.
- A male or female aged 6 months to under 10 years at the time of the survey.
- Signed informed consent or thumb-printed and witnessed informed consent was obtained from the parent(s)/LAR(s) of the child.
Participants whose parent(s)/Legally Acceptable Representative(s) [LAR(s)], in the opinion of the investigator, could and would comply with the requirements of the protocol.
- Had current active participation in any trial involving administration of an investigational malaria vaccine or malaria drug.
Child was in care.
Trial location(s)
Study documents
If you wish to request for full study report, please contact - [email protected]
Results overview
Results posted on ClinicalTrials.gov
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.